Financial insights of TECX

MyFinsight

For the quarter ending 2026-03-31.

Income Statement	2026-03-31	2025-12-31
Research and development	-	-21,204*
General and administrative	-	5,137*
Total operating expenses	-	-16,067
Loss from operations	-	16,067*
Research and development expense-Employee Related Expenses	-4,119	-
Interest income	-	2,825*
General and administrative expense-Employee Related Expenses	-1,755	-
Interest expense	-	16*
Research and development expense-Research And Pre-Clinical Expenses	-1,578	-
Change in fair value of safe liabilities	-	0*
Research and development expense-Clinical And Development Expenses	-9,664	-
Other expense	-	-30*
Research and development expense-Chemistry Manufacturing And Control Expenses	-3,518	-
Total other income, net	-	2,779*
Research and development expense-Non-Clinical Science Expenses	-314	-
Loss before income tax	-	18,846*
Non-controllable expenses	-2,822	-
Income tax expense	-	308*
Other income	-1,471	-
Net loss	-25,241	18,538

Basic EPS	-1.34	-1.012
Diluted EPS	-1.34	-1.012
Basic Average Shares	18,769,004	18,322,533
Diluted Average Shares	18,769,004	18,322,533

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.